Trial Profile
A National, Multi Center, Randomized, Open-label, Phase II Trial of Erlotinib Versus Combination of GC as (Neo)Adjuvant Treatment in Stage IIIA-N2 NSCLC With Sensitizing EGFR Mutation in Exon 19 or 21(EMERGING)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms EMERGING; TARGET
- 08 Jun 2021 Results of final overall survival analysis (data cutoff: 29 Jan 2021) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 13 Jun 2019 Primary endpoint (The objective response rate (ORR) in neoadjuvant treatment) has not been met.
- 13 Jun 2019 Results (n=72) published in the Journal of Clinical Oncology.